NTPase Subclass as A Cancer-Related Drug Target and Biomarker

Target Name: NTPCR

NCBI ID: G84284

NTPase Subclass as A Cancer-Related Drug Target and Biomarker

Non-coding RNA (ncRNA) plays a crucial role in various biological processes, including gene regulation, DNA replication, and responses to environmental stimuli. One subclass of ncRNA, named NTPases, has been identified as a potential drug target or biomarker in the context of human cancer. In this article, we will explore the NTPase subclass, with a focus on the human cancer-related NTPase (NTPCR).

What is NTPCR?

NTPCR (Nucleotide Translocation-Inspired DNA Polymorphism-Coupled Repeat Repeat) is a type of gene expression regulation that involves the transfer of a targeted DNA segment from one gene to another through a protein-mediated process. This process is driven by the NTPase enzyme, which plays a crucial role in the regulation of gene expression and DNA replication.

NTPCR is a highly conserved family of enzymes that has been identified in various organisms, including bacteria, archaea, and eukaryotes. These enzymes share a common catalytic core and a conserved active site, but differ in their secondary structure and subcellular localization.

In human cancer, NTPCR has been implicated in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis. Several studies have identified altered levels of NTPCR activity in human cancer tissues, which may contribute to the development and progression of these diseases.

Drug Targeting NTPCR

Several drugs have been developed to target NTPCR and inhibit its activity. These drugs act by inhibiting the activity of the NTPase enzyme, leading to the inhibition of NTPCR-mediated gene expression.

One of the most well-known drugs that targets NTPCR is the PI3K inhibitor alvelium (TO-428), which is a small molecule that inhibits the activity of the NTPase enzyme. Alvelium has been shown to be effective in preclinical models of cancer, including breast and colorectal cancer.

Another drug that targets NTPCR is the DNA polymerase inhibitor NU-001, which is currently in clinical trials for the treatment of various cancers. NU-001 works by inhibiting the activity of the DNA polymerase enzyme, which is a crucial step in the DNA replication process.

Biomarker Assays

To validate the potential utility of NTPCR as a biomarker or drug target, several biomarker assays have been developed. These assays can be used to measure the levels of specific NTPCR products in cancer tissues, as well as their levels in surrounding cells.

One of the most common biomarker assays used to study NTPCR is the reverse transcription polymerase (RT-PCP) assay. This assay involves the use of a specific NTPCR enzyme to transcribe a specific DNA segment from a plasmid into RNA, which is then amplified and visualized using a radioactive tag. The amount of RNA generated by the RT-PCP assay provides an indirect measurement of the levels of the specific NTPCR enzyme in the cells.

Another biomarker assay that can be used to study NTPCR is the western blot (WB) assay. This assay involves the use of a specific NTPCR enzyme to amplify a specific DNA segment from a cell or tissue, and then the use of a radioactive tag to visualize the specific product. The amount of radioactive protein generated by the WB assay provides an indirect measurement of the levels of the specific NTPCR enzyme in the cells.

In conclusion, NTPCR is a promising drug target and biomarker in the context of human cancer. The inhibition of NTPCR activity has been shown to be effective in preclinical models of

Protein Name: Nucleoside-triphosphatase, Cancer-related

Functions: Has nucleotide phosphatase activity towards ATP, GTP, CTP, TTP and UTP. Hydrolyzes nucleoside diphosphates with lower efficiency

More Common Targets